HCW Biologics Inc (HCWB) FinancialsHCWBFinancialHCW Biologics Inc

Evaluating the bottom line, HCW Biologics Inc maintains a gross margin of -69.25%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2324.94%, while the net margin is -3849.90%. These profitability ratios, combined with a Return on Equity (ROE) of -580.56%, provide a clear picture of how effectively HCWB converts its operational activities into shareholder value.

In the context of the broader market, HCWB competes directly with industry leaders such as AQB and APUS. With a market capitalization of $6.30M, it holds a significant position in the sector. When comparing efficiency, HCWB's gross margin of -69.25% stands against AQB's N/A and APUS's N/A. Such benchmarking helps identify whether HCW Biologics Inc is trading at a premium or discount relative to its financial performance.

The company's gross margin improved dramatically to 99.83% in Q1 2026, but it reported a net loss of $15.4 million in Q2 2026, indicating ongoing financial challenges despite some positive revenue growth.